| Number | Title | Principal Investigator(s) | Enrolment Status | Publication Status | Study Description |
|---|---|---|---|---|---|
| SASL 46 | SASL Swiss Cirrhosis Cohort Study (SSciCos) | Bernsmeier, Berzigotti | not yet recruiting | study ongoing | Study summary |
| SASL 45 | Swiss registry on hepatocellular adenoma | Montserrat Fraga | recruiting | study ongoing | Study summary |
| SASL 44 | DAA Treatment Failure in Chronic Hepatitis C - The Swiss Experience | Montserrat Fraga | terminated Public database | Published: Swiss Med Wkly., 2024, 154 (6): 3698 | Study summary |
| SASL 43 | Swiss IgG4 disease cohort | M Delgado, Bern | recruiting | study ongoing | Study summary |
| SASL 42 | Autoimmune Idiopathic Disorders in HCV patients: effect of direct Antiviral Agents (DAA) | Guido Stirnimann, Giuseppe Murgia, Annalisa Berzigotti | recruiting | study ongoing | Study summary |
| SASL 40 | Swiss registry on Primar Sclerosing Cholangitis SWISS PSC | Joachim Mertens, Universitätsspital Zürich | recruiting | study ongoing | |
| SASL 39 | Swiss registry on Primary Biliary Cholangitis | Benedetta Terziroli Beretta-Piccoli, Andreas Cerny; Epatocentro Ticino, Lugano | recruiting | study ongoing | Study summary |
| SASL 38 | Swiss registry on Autoimmune Hepatitis | Benedetta Terziroli Beretta-Piccoli, Andreas Cerny; Epatocentro Ticino, Lugano | recruiting | study ongoing | Study summary |
| SASL 37 | Swiss Hepatitis B Cohort Study | Beat Müllhaupt, Universitätsspital Zürich | recruiting | study ongoing | |
| SASL 36 | The health burden of Primary Biliary Cholangitis in Switzerland | Benedetta Terziroli Beretta-Piccoli, Andreas Cerny; Epatocentro Ticino, Via Soldino 5, 6900 Lugano | terminated | Published: Clin Rev Allergy Immunol., 2018, 54: 295-306 | Study summary |
| SASL 35 | Swiss Liver Venous Thrombosis Study | Andrea De Gottardi, Inselspital Bern | recruiting | study ongoing | Study summary |
| SASL 34 | Therapy of NASH with Vitamin D3 | Andreas Geier | no longer recruiting Public database | - | Study summary |
| SASL 33 | Plasma and urine metabolomic after percutaneous thermoablation (RFA) of hepatocellular carcinoma to identify novel biomarkers | Isabelle Pache, Lausanne | no longer recruiting | study ongoing | Study summary |
| SASL 32 | Non-invasive biomarkers for HCC treated with TACE | Jean-Francois Dufour | recruiting | study ongoing | Study summary |
| SASL 31 | Prospective evaluation of HepIFN test in patients with chronic hepatitis C | Markus Heim | terminated | - | Study summary |
| SASL 30 | SAKK 77/09: A phase I open label/Phase II randomized, double-blind, multicenter study investigating the combination of RAD001 and transArterial ChemoEmbolisation (TACE) with doxorubicin in patients with hepatocellular carcinoma eligible for TACE | Jean-Francois Dufour, Dieter Köberle, Sylvain Terraz | terminated | - | Study summary |
| SASL 29 | SAKK 77/08: Sorafenib alone or in combination with everolimus in patients with unresectable hepatocellular carcinoma. A multicenter phase II trial. | Dieter Köberle, Jean-Francois Dufour | terminated | - | Study summary |
| SASL 28 | A randomized open label study evaluating the efficacy of continuous telbivudine versus lamivudine in patients with HBeAg-negative Chronic Hepatitis B who had previously achieved an undetectable viral load during 24 weeks of telbivudine therapy | Markus Heim, Darius Moradpour | terminated | - | Study summary |
| SASL 27 | EuroWilson | Darius Moradpour, Isabelle Pache, Michela Schaeppi | terminated Public database | - | |
| SASL 26 | SAKK 77/07: External beam radiotherapy for unresectable hepatocellular carcinoma. A phase I/II trial. | PD Dr. med. Ilja Ciernik (Bellinzona), Dr. med. Diana Naehrig (Basel), Prof. Stephan Bodis (Aarau), PD Dr. med. Luca Cozzi (Bellinzona) | terminated | - | |
| SASL 25 | TransArterial ChemoEmbolisation (TACE) with doxorubicin incombination with systemic administration of sorafenib for patients with hepatocellular carcinoma. | Prof. J.-F. Dufour (Bern), Prof. M. Borner (Bern), Prof. D. Candinas (Bern) | terminated | Published: Oncologist, 2010, 15:1198-204: | Study summary |
| SASL 24 | Prospektive, offene, randomisierte, kontrollierte Therapiestudie zur Wirksamkeit und Verträglichkeit einer Ther. mit PegInterferon-alfa2a + serumspiegeladaptierter Ribavirindosis vs. PegInterferon-alfa2a + gewichtsadaptierter Ribavirindosis bei Pat. mit nicht vorbehandelter chronischer Hepatitis C | Felix Stickel (Bern) | terminated | Published: Am J Gastroenterol., 2013, 108: 1176-8 | Study summary |
| SASL 23 | Protocol SAKK 77/06, SASL 23: Continuous sunitinib treatment in patients with unresectable hepatocellular carcinoma. A multi-center phase II trial | D. Köberle (St.Gallen), M. Montemurro (CHUV Lausanne), M. Borner (Inselspital Bern), P. E. Majno (HUG Genève) | terminated Public database | - | Study summary |
| SASL 22 | A Pilot Single-Arm, Uncontrolled Study of Treatment with Pegylated Interferon-Alpha2a, Ribavirin and Insulin Sensitizer Pioglitazone of Insulin Resistance (with the Exception of Diabetes) in Hepatitis C Virus Infection (The INSPIRED HCV Study) | F. Negro | terminated Public database | Published: Journal of Hepatology, 2008, 49: 295-298 | Study summary |
| SASL 21 | Prospective evaluation of non-invasive fibrosis markers in patients with hepatitis C | J.Reichen | terminated | - | |
| SASL 20 | Treatment with rosiglitazone (Avandia) of patients suffering from non-alcoholic steatohepatitis (NASH). A randomized, plazebo-controlled, double-blinded study | J.F.Dufour | terminated | - | |
| SASL 19 | Prospective randomized controlled multicenter trial comparing transarterial chemoembolization (TACE) versus TACE plus radio frequency thermoablation for the treatment of hepatocellular carcinomas in patients on the waiting list for liver transplantation | P.Majno, M.H.Heim, A.Denys | terminated | - | Study summary |
| SASL 18 | Treatment of acute hepatitis c with pegylated interferon alpha-2b: correlation between hcv rna kinetics and immunological response | F.Negro | terminated | Published: Journal of Hepatology, 2005, 42: 323-328 | |
| SASL 17 | Ribavirin / pegasys treatment of recurrent hepatitis C after liver transplant | F.Negro | terminated Public database | Published: Transplant Infectious Disease , 2009, 11: 33-39 | |
| SASL 16 | Molecular pathogenesis of cholestatic liver disease: analysis of gene polymorphisms in patients with familial or drug-induced cholestasis or intrahepatic cholestasis of pregnancy | G.Kullak-Ublick | terminated | Published: Pharmacogenetics, 2004, 14: 91 | |
| SASL 15 | Treatment with 40 kd branched-peg-interferon alfa-2a and ribavirin of interferon-naive hepatitis C patients with advanced fibrosis or cirrhosis | B.Helbling. E.L.Renner | terminated | Published: Journal of Viral Hepatitis, 2006, 13: 76 | |
| SASL 14 | Treatment with 12 kD PEG-Interferon alfa-2b and ribavirin of interferon-naive patients with chronic hepatitis C and up to moderate fibrosi | B.Meyer-Wyss | terminated | Published: Journal of Viral Hepatitis, 2006, 13: 457 | |
| SASL 12 | Treatment with alpha-tocopherol and ursodeoxycholic acid of patients with non-alcoholic steatohepatitis (NASH) | B.Müllhaupt | terminated | - | |
| SASL 11 | Treatment with alpha-tocopherol and ursodeoxycholic acid of patients with non-alcoholic steatohepatitis (NASH) | J.-F.Dufour | terminated | Published: Clinical Gastroenterology and Hepatology, 2006, 4: 1537-1543 | |
| SASL 10 | Ribavirin and interferon combination in chronic hepatitis c patients not responding to interferon-alpha monotherapy | E.L.Renner | terminated | - | |
| SASL 9 | Reinduction therapy with interferon alpha-2b and ribavirin in interferon monotherapy relapse patients with chronic hepatitis C | J. Borovicka | terminated | Published: Swiss Medical Weekly, 2003, 133: 455-460 | |
| SASL 8 | Interferon alpha +/- amantadine in interferon naive patients with chronic hepatitis C | B.Helbling, E.L.Renner | terminated | Published: Hepatology, 2002, 35: 447 |